Business
Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman
MONTREAL, November 19, 2025--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke and Dr. Alan Korman to its Scientific Advisory Board.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/f5039ddb8bf21489dd2e54ef4cf6bc17"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pTogYWDoMxi_V_sA4gw2ew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f5039ddb8bf21489dd2e54ef4cf6bc17","width":480,"height":252}},"lazy":false},{"type":"text","content":"MONTREAL, November 19, 2025--(BUSINESS WIRE)--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke and Dr. Alan Korman to its Scientific Advisory Board.","length":290,"tagName":"p"},{"type":"text","content":"Dr. Alan Korman, Ph.D., Chief Scientific Officer at BlueSphere Bio, is a recognized world pioneer in immunology and cancer immunology with over 30 years of experience in the industry. Prior to joining BlueSphere, he served as the Senior Vice-President of Human Immunology at Vir Biotechnology. Before that, Dr. Korman was the Vice-President of Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS). Earlier, he worked at Medarex in various roles including Vice-President of Discovery Research. While at BMS and Medarex, Dr. Korman led the discovery of the immune checkpoint approaches for cancer immune therapy, including the world’s first inhibitor ipilimumab (anti-CTLA-4 Yervoy®), the world’s first PD-1 inhibitor nivolumab (anti-PD-1 Opdivo®) and its combination with ipilimumab, as well as the world’s first LAG-3 inhibitor relatlimab (anti-LAG-3) in combination with nivolumab. His work has meaningfully advanced the field of cancer therapy and greatly impacted the life of countless cancer patients. Furthermore, Alan’s experience in developing pH-based biotherapeutics will be critical as Ability expands its portfolio of best-in-class logic-gated T cell engagers.","length":1174,"tagName":"p"},{"type":"text","content":"Dr. John Burke, Ph.D., is an entrepreneur, pioneer, and leader in the biotech and systems pharmacology industries. He is currently the Chief Pharmacology Officer at Reverb Therapeutics. Prior to that, he was the Chief Executive Officer and cofounder of Applied BioMath, which after 10 ye...